Damora Therapeutics, Inc.
DMRADamora Therapeutics, Inc. in brief
Damora Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Denmark. Its market value was $1.3 B on 26 October 2026, which makes it the 8,102nd largest listed company in the world and the 39th largest in Denmark on this site. Its shares trade under the symbol DMRA (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Damora Therapeutics, Inc.
We are a biopharmaceutical company developing therapies for the treatment of hematologic disorders. In our previously announced Asset Acquisition (as defined below), we bolstered our pipeline with the addition of three product candidates designed to treat myeloproliferative neoplasms, a group of related, chronic disorders of the bone marrow. Our lead product candidate, DMR-001, targets mutant forms of the calcium binding protein calreticulin, which are collectively known as mutCALR. We have exercised our Option to license exclusive worldwide development and commercialization rights to DMR-001 from Paragon Therapeutics, Inc., pursuant to the Antibody Discovery and Option Agreement, dated as of October 7, 2025, by and among Paragon, Paramora Holding LLC and Pre-Acquisition Damora (as defined below). We intend to develop DMR-001 for the treatment of essential thrombocythemia, an MPN associated with the overproduction of platelets, and myelofibrosis, an MPN involving the overproliferation of blood cells and deposition of fibrous material in the bone marrow and spleen. Approximately 25% and 35% of cases of ET and MF, respectively, are caused by mutCALR rather than mutations in Janus-associated kinase 2. In contrast to marketed therapies for ET and MF, DMR-001 is designed to selectively target cells that express mutCALR while avoiding the adverse effects associated with non-specific cytoreductive drugs. Furthermore, DMR-001 was designed to have increased affinity, potency and a prolonged half-life when compared with other antibodies in development that target mutCALR. We believe that the potential combination of increased clinical activity and improved pharmacokinetics of DMR-001 positions it as a potential best-in-class therapy for ET and MF. We also have the option to license exclusive worldwide development and commercialization rights from Paragon of two other mutCALR-targeting product candidates, DMR-002 and DMR-003, pursuant to the Paragon Option Agreement.
Damora Therapeutics, Inc. timeline
- 2020
- 🔔· approximateInitial public offering on Nasdaq
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 🔔Initial public offering as Galecto Inc.Final prospectus filed with the SEC on 30 October 2020; shares registered for exchange trading on 23 October 2020.
- 2026
- ✎Renamed Damora Therapeutics, Inc.Formerly Galecto Inc..
Events of Damora Therapeutics, Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Denmark: #60 (Jan 2021) · #97 (Jan 2022) · #110 (Dec 2022) · #91 (Jul 2023) · #123 (Jan 2024) · #1 (Mar 2026) · #40 (Oct 2026) · #39 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 5.5×
- Free cash flow yield
- -3.3%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -87.8%
- Liabilities / assets
- 7.7%
- Payout ratio
- 0.0%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-211M | $-210M | — |
| Dec 2024 | — | — | $-22M | $-21M | — |
| Dec 2023 | — | — | $-40M | $-38M | — |
| Dec 2022 | — | — | $-61M | $-62M | — |
| Dec 2021 | — | — | $-52M | $-52M | — |
| Dec 2020 | — | — | $-34M | $-35M | — |
| Dec 2019 | — | — | $39M | $-37M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-7M | — | — | $3.98 | $0.00 |
| Dec 2024 | $-19M | — | — | $-18.53 | $0.00 |
| Dec 2023 | $-37M | — | — | $-36.08 | — |
| Dec 2022 | $-43M | $0M | $-43M | $-2.43 | — |
| Dec 2021 | $-52M | $0M | $-53M | $-2.05 | $0.00 |
| Dec 2020 | $-38M | — | — | $-7.62 | $0.00 |
| Dec 2019 | $-19M | — | — | $-161.82 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-32M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 4, 202610-QQuarterly report · period to Sep 2026
- Aug 10, 202610-QQuarterly report · period to Jun 2026
- Jul 20, 20268-KCurrent reportMaterial agreement · Bylaws amended · Regulation FD disclosure
- Jun 17, 20268-KCurrent reportShareholder vote
- May 12, 202610-QQuarterly report · period to Mar 2026
- May 4, 20268-KCurrent reportDirectors or officers changed
- Apr 29, 2026DEF 14AProxy statement
- Apr 20, 20268-KCurrent reportAuditor change
- Mar 23, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Mar 19, 202610-KAnnual report · period to Dec 2025
- Mar 10, 20268-KCurrent reportResults of operations · Bylaws amended · Regulation FD disclosure
- Feb 11, 20268-KCurrent reportMaterial agreement
Official filings of Damora Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-211 M
- Net income
- $-210 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $261 M
- Total liabilities
- $20 M
- Total equity
- $239 M
As of December-2025
Top 100 institutional investors in Damora Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 9,549,056 | New | 15.43% | $203 M | Nov 10, 2026 |
| 2 | Fairmount Funds Management LLC | 8,713,000 | New | 14.07% | $185 M | Nov 16, 2026 |
| 3 | Avoro Capital Advisors LLC | 3,783,000 | New | 6.11% | $81 M | Nov 16, 2026 |
| 4 | Venrock Adviser, LLC | 3,603,595 | New | 5.82% | $77 M | Nov 16, 2026 |
| 5 | BlackRock, Inc. | 3,514,573 | New | 5.68% | $75 M | Nov 13, 2026 |
| 6 | Ra Capital Management, L.P. | 2,399,702 | New | 3.88% | $51 M | Nov 16, 2026 |
| 7 | Remedium Capital Partners, LLC | 2,045,473 | New | 3.30% | $44 M | Nov 13, 2026 |
| 8 | Commodore Capital LP | 1,939,000 | New | 3.13% | $41 M | Nov 16, 2026 |
| 9 | Bellevue Group AG | 1,919,383 | New | 3.10% | $41 M | Nov 16, 2026 |
| 10 | Jpmorgan Chase & Co | 1,872,628 | New | 3.02% | $40 M | Nov 12, 2026 |
| 11 | State Street Corp | 1,780,897 | New | 2.88% | $38 M | Nov 12, 2026 |
| 12 | Braidwell LP | 1,747,659 | New | 2.82% | $37 M | Nov 16, 2026 |
| 13 | Viking Global Investors LP | 1,207,985 | New | 1.95% | $26 M | Nov 16, 2026 |
| 14 | Geode Capital Management, LLC | 1,203,286 | New | 1.94% | $26 M | Nov 6, 2026 |
| 15 | UBS Group AG | 1,082,845 | New | 1.75% | $23 M | Nov 10, 2026 |
| 16 | Blackstone Inc. | 1,035,122 | New | 1.67% | $22 M | Nov 16, 2026 |
| 17 | Balyasny Asset Management L.P. | 973,000 | New | 1.57% | $21 M | Nov 16, 2026 |
| 18 | Siren, L.L.C. | 900,000 | New | 1.45% | $19 M | Nov 12, 2026 |
| 19 | Cormorant Asset Management, LP | 800,000 | New | 1.29% | $17 M | Nov 16, 2026 |
| 20 | Vanguard Capital Management LLC | 557,495 | New | 0.90% | $12 M | Nov 13, 2026 |
| 21 | Stempoint Capital LP | 506,067 | New | 0.82% | $11 M | Nov 16, 2026 |
| 22 | Ameriprise Financial Inc | 474,449 | New | 0.77% | $10 M | Nov 16, 2026 |
| 23 | Charles Schwab Investment Management Inc | 441,650 | New | 0.71% | $9 M | Nov 16, 2026 |
| 24 | Adage Capital Partners GP, L.L.C. | 400,000 | New | 0.65% | $9 M | Nov 16, 2026 |
| 25 | Northern Trust Corp | 397,907 | New | 0.64% | $8 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Vestal Point Capital, LP | 395,000 | New | 0.64% | $8 M | Nov 16, 2026 |
| 27 | Citadel Advisors LLC | 388,042 | New | 0.63% | $8 M | Nov 16, 2026 |
| 28 | Vanguard Portfolio Management LLC | 375,677 | New | 0.61% | $8 M | Nov 13, 2026 |
| 29 | Affinity Asset Advisors, LLC | 375,000 | New | 0.61% | $8 M | Nov 13, 2026 |
| 30 | Goldman Sachs Group Inc | 316,509 | New | 0.51% | $7 M | Nov 16, 2026 |
| 31 | Vanguard Fiduciary Trust Co | 304,507 | New | 0.49% | $6 M | Nov 13, 2026 |
| 32 | Seven Fleet Capital Management LP | 288,439 | New | 0.47% | $6 M | Nov 16, 2026 |
| 33 | Perceptive Advisors LLC | 282,524 | New | 0.46% | $6 M | Nov 16, 2026 |
| 34 | ADAR1 Capital Management, LLC | 281,000 | New | 0.45% | $6 M | Nov 16, 2026 |
| 35 | Nantahala Capital Management, LLC | 278,000 | New | 0.45% | $6 M | Nov 13, 2026 |
| 36 | Ikarian Capital, LLC | 275,710 | New | 0.45% | $6 M | Nov 16, 2026 |
| 37 | Millennium Management LLC | 266,211 | New | 0.43% | $6 M | Nov 16, 2026 |
| 38 | Marshall Wace, LLP | 223,853 | New | 0.36% | $5 M | Nov 13, 2026 |
| 39 | Jennison Associates LLC | 212,425 | New | 0.34% | $5 M | Nov 16, 2026 |
| 40 | Bank Of Montreal /can/ | 205,519 | New | 0.33% | $4 M | Nov 9, 2026 |
| 41 | Sofinnova Investments, Inc. | 149,197 | New | 0.24% | $3 M | Nov 16, 2026 |
| 42 | PFM Health Sciences, LP | 144,362 | New | 0.23% | $3 M | Nov 16, 2026 |
| 43 | Bank of New York Mellon Corp | 143,750 | New | 0.23% | $3 M | Nov 5, 2026 |
| 44 | Nuveen, LLC | 141,509 | New | 0.23% | $3 M | Nov 10, 2026 |
| 45 | Kalehua Capital Management LLC | 139,000 | New | 0.22% | $3 M | Nov 13, 2026 |
| 46 | DV Equities, LLC | 130,000 | New | 0.21% | $3 M | Nov 16, 2026 |
| 47 | Morgan Stanley | 95,217 | New | 0.15% | $2 M | Nov 13, 2026 |
| 48 | Bank Of America Corp /de/ | 93,188 | New | 0.15% | $2 M | Nov 16, 2026 |
| 49 | Boothbay Fund Management, LLC | 91,261 | New | 0.15% | $2 M | Nov 16, 2026 |
| 50 | Rhumbline Advisers | 63,491 | New | 0.10% | $1 M | Nov 10, 2026 |
| 51 | Quadrature Capital Ltd | 61,463 | New | 0.10% | $1 M | Nov 13, 2026 |
| 52 | Alliancebernstein L.P. | 55,710 | New | 0.09% | $1 M | Nov 16, 2026 |
| 53 | Swiss National Bank | 52,900 | New | 0.09% | $1 M | Nov 12, 2026 |
| 54 | Woodline Partners LP | 51,782 | New | 0.08% | $1 M | Nov 16, 2026 |
| 55 | XTX Topco Ltd | 50,943 | New | 0.08% | $1 M | Nov 16, 2026 |
| 56 | Price T Rowe Associates Inc /MD/ | 43,170 | -5,573 (-11.43%) | 0.07% | $1 M | Nov 16, 2026 |
| 57 | Squarepoint Ops LLC | 39,410 | New | 0.06% | $1 M | Nov 9, 2026 |
| 58 | Rafferty Asset Management, LLC | 31,412 | New | 0.05% | $1 M | Nov 13, 2026 |
| 59 | California State Teachers Retirement System | 31,309 | New | 0.05% | $1 M | Nov 13, 2026 |
| 60 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 31,139 | New | 0.05% | $1 M | Nov 16, 2026 |
| 61 | BNP Paribas Financial Markets | 30,431 | New | 0.05% | $1 M | Nov 12, 2026 |
| 62 | Invesco Ltd. | 28,050 | New | 0.05% | $1 M | Nov 12, 2026 |
| 63 | MetLife Investment Management, LLC | 26,976 | New | 0.04% | $1 M | Nov 16, 2026 |
| 64 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 25,006 | New | 0.04% | $1 M | Nov 16, 2026 |
| 65 | Aquatic Capital Management LLC | 24,556 | New | 0.04% | $1 M | Nov 16, 2026 |
| 66 | VANGUARD ASSET MANAGEMENT, Ltd | 19,515 | New | 0.03% | $0 M | Nov 13, 2026 |
| 67 | Vanguard Global Advisers, LLC | 19,043 | New | 0.03% | $0 M | Nov 13, 2026 |
| 68 | New York State Common Retirement Fund | 18,800 | New | 0.03% | $0 M | Nov 17, 2026 |
| 69 | Quantinno Capital Management LP | 17,277 | New | 0.03% | $0 M | Nov 13, 2026 |
| 70 | Optimize Financial Inc. | 16,023 | New | 0.03% | $0 M | Nov 12, 2026 |
| 71 | Citigroup Inc | 15,854 | New | 0.03% | $0 M | Nov 4, 2026 |
| 72 | Virtus Investment Advisers, LLC | 15,271 | New | 0.02% | $0 M | Nov 12, 2026 |
| 73 | Corient Private Wealth LP | 13,798 | New | 0.02% | $0 M | Nov 16, 2026 |
| 74 | Police & Firemen's Retirement System of New Jersey | 12,955 | New | 0.02% | $0 M | Nov 9, 2026 |
| 75 | Strs Ohio | 12,800 | New | 0.02% | $0 M | Oct 30, 2026 |
| 76 | Wells Fargo & Company/mn | 12,743 | New | 0.02% | $0 M | Nov 16, 2026 |
| 77 | Two Sigma Investments, LP | 11,873 | New | 0.02% | $0 M | Nov 16, 2026 |
| 78 | Profund Advisors LLC | 11,573 | New | 0.02% | $0 M | Oct 29, 2026 |
| 79 | Susquehanna International Group, LLP | 10,939 | New | 0.02% | $0 M | Nov 16, 2026 |
| 80 | Zurcher Kantonalbank (Zurich Cantonalbank) | 10,582 | New | 0.02% | $0 M | Nov 10, 2026 |
| 81 | State Of Wisconsin Investment Board | 10,429 | New | 0.02% | $0 M | Nov 16, 2026 |
| 82 | SEI Investments Co | 9,921 | New | 0.02% | $0 M | Nov 10, 2026 |
| 83 | KLP Kapitalforvaltning As | 9,700 | New | 0.02% | $0 M | Nov 10, 2026 |
| 84 | Vanguard Investments Australia, Ltd. | 9,279 | New | 0.01% | $0 M | Nov 13, 2026 |
| 85 | Persistent Asset Partners Ltd | 8,625 | New | 0.01% | $0 M | Nov 13, 2026 |
| 86 | Legal & General Group Plc | 5,280 | New | 0.01% | $0 M | Nov 16, 2026 |
| 87 | Royal Bank Of Canada | 2,509 | New | 0.00% | $0 M | Nov 16, 2026 |
| 88 | Tower Research Capital LLC (TRC) | 2,452 | New | 0.00% | $0 M | Nov 16, 2026 |
| 89 | Vestcor Inc | 1,984 | New | 0.00% | $0 M | Nov 12, 2026 |
| 90 | China Universal Asset Management Co., Ltd. | 1,600 | New | 0.00% | $0 M | Oct 28, 2026 |
| 91 | State of Wyoming | 1,363 | New | 0.00% | $0 M | Oct 28, 2026 |
| 92 | Sterling Capital Management LLC | 1,359 | New | 0.00% | $0 M | Oct 22, 2026 |
| 93 | Rockefeller Capital Management L.P. | 577 | New | 0.00% | $0 M | Nov 13, 2026 |
| 94 | Global Retirement Partners, LLC | 191 | New | 0.00% | $0 M | Nov 10, 2026 |
| 95 | GAMMA Investing LLC | 91 | New | 0.00% | $0 M | Oct 8, 2026 |
| 96 | Parkside Financial Bank & Trust | 70 | New | 0.00% | $0 M | Oct 27, 2026 |
| 97 | Harbour Investments, Inc. | 40 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 98 | Farther Finance Advisors, LLC | 40 | New | 0.00% | $0 M | Oct 8, 2026 |
| 99 | Osaic Holdings, Inc. | 39 | New | 0.00% | $0 M | Nov 12, 2026 |
| 100 | US Bancorp \de\ | 34 | New | 0.00% | $0 M | Nov 5, 2026 |
Superinvestors holding Damora Therapeutics, Inc.
1 of the well-known investors value.today follows, from their newest Form 13F.
- Viking Global Investors · Andreas Halvorsen$26 Mnew · Sep 30, 2026
Mutual funds holding Damora Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Growth Company FundFidelity Management & Research Company LLC | 1.83 M | $46 M | — | 0.05% | +4.0% | May 31, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 1.36 M | $35 M | — | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC | 834,040 | $24 M | 1.3% | 0.27% | no change | Jul 31, 2026 |
| 🇺🇸 JPMorgan Small Cap Growth FundJ.P. Morgan Investment Management Inc. | 741,346 | $19 M | — | 0.74% | new | Jun 30, 2026 |
| 🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc. | 714,931 | $19 M | — | 0.17% | +662% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 583,679 | $17 M | 0.94% | 0.05% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Growth Company K6 FundFidelity Management & Research Company LLC | 535,388 | $13 M | — | 0.05% | +2.6% | May 31, 2026 |
| 🇺🇸 Select Health Care PortfolioFidelity Management & Research Company LLC | 500,000 | $12 M | — | 0.22% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC | 410,184 | $12 M | 0.66% | 0.26% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Stock Selector Small Cap FundFidelity Management & Research Company LLC | 403,200 | $12 M | 0.65% | 0.16% | no change | Jul 31, 2026 |
| 🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC | 454,559 | $11 M | — | 0.21% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Growth Company FundFidelity Management & Research Company LLC | 452,806 | $11 M | — | 0.05% | +4.2% | May 31, 2026 |
| 🇺🇸 Fidelity Series Small Cap Opportunities FundFidelity Management & Research Company LLC | 308,400 | $9 M | 0.50% | 0.19% | no change | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 339,291 | $9 M | — | 0.06% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC | 298,142 | $9 M | 0.48% | 0.39% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Advisor Health Care FundFidelity Management & Research Company LLC | 280,000 | $8 M | 0.45% | 0.26% | no change | Jul 31, 2026 |
| 🇺🇸 JPMorgan Small Cap Blend FundJ.P. Morgan Investment Management Inc. | 238,497 | $6 M | — | 0.37% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 212,658 | $6 M | — | <0.01% | +5.4% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 154,350 | $4 M | — | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 129,635 | $4 M | 0.21% | 0.05% | new | Jul 31, 2026 |
| 🇺🇸 VIP Health Care PortfolioFidelity Management & Research Company LLC | 118,000 | $3 M | — | 0.27% | no change | Jun 30, 2026 |
| 🇺🇸 VIP Contrafund PortfolioFidelity Management & Research Company LLC | 105,500 | $3 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 95,134 | $2 M | — | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 93,464 | $2 M | — | <0.01% | +13% | May 31, 2026 |
| 🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I | 78,833 | $2 M | — | 0.15% | new | May 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 65,690 | $2 M | 0.11% | 0.05% | new | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 57,671 | $2 M | — | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 40,687 | $1 M | 0.07% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Fundamental Small-Mid Cap ETFFidelity Management & Research Company LLC | 37,030 | $1 M | 0.06% | 0.07% | +1.9% | Jul 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 37,900 | $1 M | — | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 36,683 | $1 M | — | <0.01% | new | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 34,442 | $1 M | — | 0.06% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 33,695 | $1 M | — | <0.01% | +14% | May 31, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 31,640 | $1 M | — | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 31,560 | $1 M | — | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 25,558 | $1 M | 0.04% | 0.05% | new | Jul 31, 2026 |
| 🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC | 24,293 | $1 M | 0.04% | 0.14% | +344% | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 26,962 | $1 M | — | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 27,510 | $1 M | — | <0.01% | +18% | May 31, 2026 |
| 🇺🇸 Fidelity Advisor New Insights FundFidelity Management & Research Company LLC | 23,800 | $1 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 23,261 | $1 M | — | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 19,170 | $0 M | — | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC | 17,196 | $0 M | 0.03% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 18,200 | $0 M | — | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 17,856 | $0 M | — | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 16,733 | $0 M | — | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index ETFFidelity Management & Research Company LLC | 16,469 | $0 M | — | <0.01% | new | May 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 15,278 | $0 M | — | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 13,967 | $0 M | — | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 12,500 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Opportunistic Insights FundFidelity Management & Research Company LLC | 12,800 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 11,790 | $0 M | — | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 10,752 | $0 M | — | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 9,376 | $0 M | 0.02% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 8,166 | $0 M | — | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 8,143 | $0 M | 0.01% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 7,185 | $0 M | — | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 5,929 | $0 M | <0.01% | 0.05% | new | Jul 31, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 6,483 | $0 M | — | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 6,223 | $0 M | — | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 5,305 | $0 M | <0.01% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 5,553 | $0 M | — | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 4,710 | $0 M | <0.01% | 0.05% | new | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 4,845 | $0 M | — | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 3,954 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc. | 4,323 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 4,262 | $0 M | — | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 3,578 | $0 M | — | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 3,204 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 3,349 | $0 M | — | 0.06% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 2,600 | $0 M | — | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 2,319 | $0 M | — | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Morningstar Small-Cap ETFBlackRock Fund Advisors | 2,013 | $0 M | <0.01% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 1,869 | $0 M | — | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Biotechnology Ultrasector ProfundProFund Advisors LLC | 1,693 | $0 M | — | 0.02% | — | Apr 30, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 1,392 | $0 M | — | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 1,348 | $0 M | — | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 1,206 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 1,076 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 TIAA Separate Account VA-1 - Stock Index AccountTeachers Advisors, LLC | 1,017 | $0 M | — | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 942 | $0 M | — | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 794 | $0 M | — | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Life Stock Index FundTeachers Advisors, LLC | 717 | $0 M | — | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc. | 167 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 84 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Damora Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Jennifer JarrettDirector, President and CEO, Director | Buy | +12,500 | $20.23 | $253 K | 512,500 | Form 4 |
| filed | Garrett WinslowGeneral Counsel | Sell | -245 | $29.98 | $7 K | 2,289 | Form 4 |
| filed | Garrett WinslowGeneral Counsel | Option exercise | +680 | — | — | 2,534 | Form 4 |
| filed | Jennifer JarrettSee Remarks, Director | Grant or award | +500,000 | — | — | 500,000 | Form 4 |
| filed | Fairmount Healthcare Fund II L.P.10% owner | Option exerciseindirect | +5.81 M | — | — | 5.81 M | Form 4 |
| filed | Julianne BrunoDirector | Option exercise | +129,000 | — | — | 137,032 | Form 4 |
| filed | Fairmount Healthcare Fund II L.P.10% owner | Option exerciseindirect | +2.90 M | — | — | 2.90 M | Form 4 |
| filed | Sherwin SattarzadehChief Operating Officer | Grant or award | +190,376 | — | — | 190,376 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Damora Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-25 reverse split
| Dividend, quarter | Per share | |
|---|---|---|
| Q1 2026 | $0.000 |
Trading halts
- 2025-11-12 14:56 UTC, code LUDP, resumed 15:01 UTC
- 2025-11-11 19:42 UTC, code LUDP, resumed 19:47 UTC
- 2025-11-11 19:10 UTC, code LUDP, resumed 19:20 UTC
- 2025-11-10 15:23 UTC, code LUDP, resumed 15:28 UTC
- 2025-11-10 15:12 UTC, code LUDP, resumed 15:22 UTC
Fails to deliver
- : 147 shares at $21.09
- : 2,173 shares at $21.53
- : 36,631 shares at $18.44
- : 329 shares at $18.43
- : 333 shares at $20.56
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Damora Therapeutics, Inc. scorecard#
Passes 2 of the 13 checks that could be worked out. Fiscal year 2025; market cap of Oct 26, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median5.5×Price to book 5.5× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-3.3%Free cash flow is -3.3% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✓Earnings per share grew in the newest year3.98 vs -18.53Diluted EPS 3.98 in fiscal 2025 against -18.53 the year before (report's currency).
- ✗Net income higher than five years earlier-$210 M-$210 M in fiscal 2025 against -$35 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$210 MNet income -$210 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-165.6%-165.6% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities13.0×Current ratio 12.98 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 2
- ✗Pays a dividendNoNo dividends in fiscal 2025.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year17.8%Diluted shares up 17.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Damora Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Research and development | 27+320%— | 6.4−73.1%— | 24−50.7%— | 48+25.2%— | 38+56.3%— | 25+24.8%— | 20—— | |
| General and administrative | 9.7−7.8%— | 10−17.2%— | 13−2.4%— | 13−5.4%— | 14+52.5%— | 9.0+269%— | 2.4—— | |
| Operating expenses | 211+847%— | 22−44.2%— | 40−34.8%— | 61+17.2%— | 52+55.3%— | 34−13.7%— | 39—— | |
| Operating income | −211—— | −22—— | −40—— | −61—— | −52—— | −34r34−186%— | 39—— | |
| Net interest income | 1.2+38.3%— | 0.8−50.0%— | 1.7+134%— | 0.7+363%— | 0.2—— | — | — | |
| Other non-operating income (expense) | 1.1+25.6%— | 0.9−44.6%— | 1.6—— | −0.4−188%— | 0.5—— | −1.2−149%— | 2.5—— | |
| Income before tax | −210—— | −21—— | −38—— | −62—— | −52—— | −35—— | −37—— | |
| Income tax | 0.1+22.0%— | 0.0—— | 0—— | 0—— | 0—— | 0—— | 0—— | |
| Net income including minority interests | −210—— | −21—— | −38—— | −62—— | −52—— | −35—— | −37—— | |
| Net income attributable to shareholders | −210—— | −21—— | −38—— | −62—— | −52—— | −35—— | −37—— | |
| Earnings per share, basic | 3.98—— | -18.53—— | -36.08r-1.44—— | -2.43—— | -2.05—— | -7.62—— | -161.82—— | |
| Earnings per share, diluted | 3.98—— | -18.53—— | -36.08r-1.44—— | -2.43—— | -2.05—— | -7.62—— | -161.82—— | |
| Shares, weighted average (basic) | 1.4+17.8%— | 1.2+8.9%— | 1.1r27−95.8%— | 25+0.6%— | 25—— | — | — | |
| Shares, weighted average (diluted) | 1.4+17.8%— | 1.2+8.9%— | 1.1r27−95.8%— | 25+0.6%— | 25+452%— | 4.6+1659%— | 0.3—— | |
| Dividends per share | 0.00—— | 0.00—— | — | — | 0.00—— | 0.00—— | — | |
| Balance sheet | ||||||||
| Cash and cash equivalents | 258+1717%98.9% | 14−34.0%82.7% | 21−34.5%56.2% | 33−47.6%44.8% | 63−61.8%51.2% | 164+1348%95.3% | 11—20.0% | |
| Short-term investments | 0—0.0% | — | 12−57.4%30.6% | 27−27.1%37.5% | 38—30.8% | — | — | |
| Other current assets | 2.8+5.1%1.1% | 2.7−26.5%15.5% | 3.6−1.7%9.5% | 3.7−62.8%5.0% | 9.9+73.5%8.1% | 5.7+11.6%3.3% | 5.1—9.0% | |
| Current assets | 260+1447%100.0% | 17−54.2%98.3% | 37−42.5%96.2% | 64−42.0%87.3% | 110−35.0%90.1% | 169+202%98.7% | 56—99.1% | |
| Property, plant and equipment | 0.0−36.8%0.0% | 0.1−26.9%0.3% | 0.1−78.2%0.2% | 0.4+75.9%0.5% | 0.2—0.2% | — | — | |
| Right-of-use (leased) assets | 0.1−6.8%0.0% | 0.1−70.4%0.4% | 0.2−69.5%0.6% | 0.8−2.9%1.1% | 0.8−5.8%0.7% | 0.9+197%0.5% | 0.3—0.5% | |
| Total assets | 261+1421%100% | 17−55.2%100% | 38−47.8%100% | 73−40.1%100% | 122−28.8%100% | 172+203%100% | 57—100% | |
| Accounts payable | 0.4+17.8%0.2% | 0.4−77.8%2.2% | 1.7−49.2%4.5% | 3.4+119%4.6% | 1.5−46.3%1.3% | 2.9−14.4%1.7% | 3.3—5.9% | |
| Current liabilities | 20+1576%7.7% | 1.2−79.5%7.0% | 5.8−47.5%15.3% | 11+144%15.2% | 4.5−18.4%3.7% | 5.6−29.8%3.2% | 7.9—14.0% | |
| Lease liabilities (non-current) | 0.1−13.1%0.0% | 0.1−7.6%0.4% | 0.1−79.9%0.2% | 0.3−26.8%0.4% | 0.4−17.2%0.4% | 0.5+156%0.3% | 0.2—0.4% | |
| Total liabilities | 20+1449%7.7% | 1.3−77.9%7.6% | 5.9−48.4%15.4% | 11+129%15.6% | 5.0−18.3%4.1% | 6.1−25.0%3.6% | 8.1—14.4% | |
| Retained earnings | −487—−187% | −278—−1620% | −256—−670% | −218—−298% | −156—−128% | −104—−60.8% | −70—−123% | |
| Shareholders' equity | 239r240+1552%91.8% | 14r16−55.2%84.5% | 32−47.6%84.6% | 62−47.3%84.4% | 117−29.2%95.9% | 165—96.4% | −71—−126% | |
| Total liabilities and equity | 261+1421%100% | 17−55.2%100% | 38−47.8%100% | 73−40.1%100% | 122−28.8%100% | 172+203%100% | 57—100% | |
| Shares outstanding | 1.6+21.3%— | 1.3+21.4%— | 1.1r27−95.8%— | 26+1.5%— | 250.0%— | 25+9617%— | 0.3—— | |
| Cash-flow statement | ||||||||
| Share-based compensation | 1.0−69.2%— | 3.2−40.3%— | 5.4−2.6%— | 5.6+24.4%— | 4.5+356%— | 1.0—— | — | |
| Cash from operating activities | −6.7—— | −19—— | −37—— | −43—— | −52—— | −38—— | −19—— | |
| Capital expenditure | — | — | — | −0.2—— | −0.2—— | — | — | |
| Acquisitions, net of cash acquired | −17—— | — | — | — | — | — | −0.3—— | |
| Cash from investing activities | −17−249%— | 12−47.8%— | 22+80.3%— | 12—— | −48—— | — | −0.3—— | |
| Shares issued | — | — | 2.9+467%— | 0.5—— | — | — | — | |
| Cash from financing activities | 267—— | — | 2.9+467%— | 0.5—— | — | 187—— | — | |
| Exchange-rate effect on cash | 0.7—— | −0.3−183%— | 0.4+45.5%— | 0.3—— | −0.9−129%— | 3.1+6693%— | 0.0—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 98+2048%— | 25+1699%— | 26+1643%— | 24+3407%— | 23*+2213%— | 1.4+29.6%— | 1.5−20.1%— | 0.7−72.5%— | 1.0*−63.6%— | 1.1—— | 1.8—— | 2.5—— | 2.8*—— | |
| General and administrative | 32+337%— | 11+554%— | 9.5+383%— | 7.0+266%— | 4.1*+139%— | 1.7−36.7%— | 2.0−29.5%— | 1.9−41.4%— | 1.7*−46.6%— | 2.7—— | 2.8—— | 3.3—— | 3.2*—— | |
| Operating expenses | 304+1770%— | 37+1068%— | 35+923%— | 31+1085%— | 202*+2740%— | 3.2−17.8%— | 3.4−38.7%— | 2.6−54.7%— | 7.1*+6.5%— | 3.8—— | 5.6—— | 5.7—— | 6.7*—— | |
| Operating income | −304—— | −37—— | −35—— | −31—— | −202*—— | −3.2—— | −3.4—— | −2.6—— | −7.1*—— | −3.8—— | −5.6—— | −5.7—— | −6.7*—— | |
| Net interest income | 12+3019%— | 4.2+9802%— | 4.1+8018%— | 3.1+4049%— | 1.0*+339%— | 0.0−71.2%— | 0.1−76.5%— | 0.1−71.2%— | 0.2*−32.9%— | 0.1—— | 0.2—— | 0.3—— | 0.3*—— | |
| Other non-operating income (expense) | 13+2914%— | 4.9+21083%— | 4.1—— | 3.1+4415%— | 1.0*+184%— | 0.0—— | −0.0−104%— | 0.1−74.2%— | 0.4*+80.1%— | −0.0—— | 0.3—— | 0.3—— | 0.2*—— | |
| Income before tax | −291—— | −32—— | −31—— | −28—— | −201*—— | −3.1—— | −3.4—— | −2.5—— | −6.7*—— | −3.9—— | −5.3—— | −5.5—— | −6.5*—— | |
| Income tax | 0.3—— | 0—— | 0.3+6275%— | 0.0+2000%— | 0.0*—— | 0−100%— | 0.0−90.5%— | 0.0—— | −0.0*—— | 0.0—— | 0.0—— | — | — | |
| Net income including minority interests | −292—— | −32—— | −31—— | −28—— | −201*—— | −3.1—— | −3.4—— | −2.5—— | −6.7*—— | −3.9—— | −5.3—— | −5.5—— | −6.5*—— | |
| Net income attributable to shareholders | −292—— | −32—— | −31—— | −28—— | −201*—— | −3.1—— | −3.4—— | −2.5—— | −6.7*—— | −3.9—— | −5.3—— | −5.5—— | −6.5*—— | |
| Earnings per share, basic | — | -0.40—— | -0.39—— | -0.62—— | — | -2.36—— | -2.60—— | -1.92—— | — | -3.39—— | -4.92r-0.20—— | -5.05r-0.20—— | — | |
| Earnings per share, diluted | — | -0.40—— | -0.39—— | -0.62—— | — | -2.36—— | -2.60—— | -1.92—— | — | -3.39—— | -4.92r-0.20—— | -5.05r-0.20—— | — | |
| Shares, weighted average (basic) | 62+4558%— | 62+4558%— | 61+4521%— | 34+2494%— | — | 1.3+15.9%— | 1.3+21.9%— | 1.3+21.9%— | — | 1.1—— | 1.1r27—— | 1.1r27—— | — | |
| Shares, weighted average (diluted) | 62+4558%— | 62+4558%— | 61+4521%— | 34+2494%— | — | 1.3+15.9%— | 1.3+21.9%— | 1.3+21.9%— | — | 1.1—— | 1.1r27—— | 1.1r27—— | — | |
| Dividends per share | — | — | — | 0.00—— | — | — | — | — | — | — | — | — | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 350—65.6% | 350+4497%65.6% | 541+5193%99.4% | 533+4364%99.5% | 258+1717%98.9% | 7.6−61.3%70.8% | 10−55.3%74.6% | 12−43.4%77.7% | 14−34.0%82.7% | 20—84.2% | 23—83.8% | 21—64.9% | 21—56.2% | |
| Short-term investments | 179—33.6% | 179—33.6% | — | — | 0—0.0% | — | — | — | — | — | — | 6.1—18.7% | 12—30.6% | |
| Other current assets | 2.8—0.5% | 2.8+30.2%0.5% | 3.1+9.1%0.6% | 2.5−15.9%0.5% | 2.8+5.1%1.1% | 2.2+45.3%20.3% | 2.8+22.1%20.6% | 3.0−11.5%19.4% | 2.7−26.5%15.5% | 1.5—6.4% | 2.3—8.4% | 3.4—10.4% | 3.6—9.5% | |
| Current assets | 531—99.8% | 531+5329%99.8% | 544+4073%100.0% | 535+3488%100.0% | 260+1447%100.0% | 9.8−53.8%91.2% | 13−48.2%95.2% | 15−51.1%97.1% | 17−54.2%98.3% | 21—90.6% | 25—92.2% | 31—94.0% | 37—96.2% | |
| Property, plant and equipment | — | — | — | — | 0.0−36.8%0.0% | 0.0−33.9%0.4% | 0.0−29.9%0.3% | 0.1−28.8%0.3% | 0.1−26.9%0.3% | 0.1—0.3% | 0.1—0.2% | 0.1—0.2% | 0.1—0.2% | |
| Right-of-use (leased) assets | 0.8—0.2% | 0.8+1053%0.2% | — | — | 0.1−6.8%0.0% | 0.1+125%0.7% | 0.1−1.3%0.5% | 0.1−52.0%0.5% | 0.1−70.4%0.4% | 0.0—0.1% | 0.1—0.3% | 0.2—0.5% | 0.2—0.6% | |
| Total assets | 533—100% | 533+4861%100% | 544+3871%100% | 535+3385%100% | 261+1421%100% | 11−54.1%100% | 14−49.8%100% | 15−52.7%100% | 17−55.2%100% | 23—100% | 27—100% | 32—100% | 38—100% | |
| Accounts payable | 6.1—1.1% | 6.1+1070%1.1% | 3.5+361%0.6% | 0.8+131%0.2% | 0.4+17.8%0.2% | 0.5+3.4%4.8% | 0.8+4.4%5.5% | 0.4−78.7%2.3% | 0.4−77.8%2.2% | 0.5—2.2% | 0.7—2.7% | 1.7—5.1% | 1.7—4.5% | |
| Current liabilities | 36—6.7% | 36+1268%6.7% | 28+948%5.1% | 24+1435%4.4% | 20+1576%7.7% | 2.6+7.5%24.4% | 2.6−29.1%19.2% | 1.6−64.1%10.1% | 1.2−79.5%7.0% | 2.4—10.4% | 3.7—13.6% | 4.3—13.3% | 5.8—15.3% | |
| Lease liabilities (non-current) | 0.9—0.2% | 0.9+1560%0.2% | — | — | 0.1−13.1%0.0% | 0.1—0.5% | 0.1—0.4% | 0.1—0.4% | 0.1−7.6%0.4% | — | — | — | 0.1—0.2% | |
| Total liabilities | 37—6.9% | 37+1251%6.9% | 28+907%5.1% | 24+1340%4.5% | 20+1449%7.7% | 2.7+11.8%25.4% | 2.7−26.2%20.0% | 1.7−61.6%10.8% | 1.3−77.9%7.6% | 2.4—10.4% | 3.7—13.6% | 4.3—13.3% | 5.9—15.4% | |
| Retained earnings | −578—−109% | −578—−109% | −546—−100% | −515—−96.2% | −487—−187% | −287—−2670% | −283—−2071% | −280—−1823% | −278—−1620% | −271—−1158% | −267—−978% | −262—−805% | −256—−670% | |
| Shareholders' equity | 496—93.1% | 496+7337%93.1% | 516+5269%94.9% | 512+3632%95.5% | 239r240+1552%91.8% | 6.7r8.0−68.2%62.1% | 9.6r11−59.3%70.2% | 14−51.3%89.2% | 14r16−55.2%84.5% | 21—89.6% | 24—86.4% | 28—86.7% | 32—84.6% | |
| Total liabilities and equity | 533—100% | 533+4861%100% | 544+3871%100% | 535+3385%100% | 261+1421%100% | 11−54.1%100% | 14−49.8%100% | 15−52.7%100% | 17−55.2%100% | 23—100% | 27—100% | 32—100% | 38—100% | |
| Shares outstanding | 62—— | 62+4564%— | 62+4561%— | 60+4460%— | 1.6+21.3%— | 1.3+5.9%— | 1.3−95.1%— | 1.3−95.1%— | 1.3+21.4%— | 1.3—— | 27—— | 27—— | 1.1r27—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 24+2838%— | 9.9+5922%— | 11+6113%— | 3.1+1651%— | 0.5*+56.8%— | 0.2−75.9%— | 0.2−80.7%— | 0.2−86.8%— | 0.3*−71.7%— | 0.7—— | 0.9—— | 1.4—— | 1.1*—— | |
| Cash from operating activities | −59—— | −17*—— | −22*—— | −21—— | 0.6*—— | −2.6*—— | −2.2*—— | −2.4—— | −4.9*—— | −3.7*—— | −4.1*—— | −5.9—— | −11*—— | |
| Cash from investing activities | — | — | — | — | — | — | — | — | 0*−100%— | 0*—— | 6.0*—— | 5.7—— | 9.6*—— | |
| Shares issued | — | — | — | — | — | — | — | — | — | — | — | — | 0*—— | |
| Cash from financing activities | — | 5.1*—— | 30*—— | 296—— | — | — | — | — | — | — | — | — | 0*—— | |
| Exchange-rate effect on cash | −0.1−151%— | 0.0*−18.2%— | −0.0*−104%— | −0.0−124%— | −0.0*—— | 0.0*−97.6%— | 0.5*—— | 0.2—— | −0.6*−302%— | 0.5*—— | −0.1*—— | −0.1—— | 0.3*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Damora Therapeutics, Inc. operates: 3 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 5 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇩🇰 Denmark | Headquarters1 subsidiary | — |
| 🇺🇸 USA | 1 office3 subsidiaries | — |
| 🇸🇪 Sweden | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Damora Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Hans T. Schambye, M.D., Ph.D. | $1.3 M | $2.1 M | $709 K | $128 |
| 2024Hans T. Schambye, M.D., Ph.D. | $1.4 M | $1.2 M | $760 K | $26 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Damora Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Auditor changedFiling
Delisting notice 1 · Auditor changed 1 · Acquisition or sale completed 2 · Directors and officers 7 · Material agreement 4 · Unregistered share sale 3 · Shareholder rights changed 1 · Bylaws or fiscal year changed 7 · Shareholder vote 3 · Results announced 1
| Filed | What happened | Filing |
|---|---|---|
| Material agreementShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Auditor changed | 8-K | |
| Directors and officers | 8-K | |
| Bylaws or fiscal year changedResults announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officersBylaws or fiscal year changed | 8-K | |
| Directors and officersUnregistered share sale | 8-K | |
| Bylaws or fiscal year changed | 8-K/A | |
| Acquisition or sale completedDirectors and officersMaterial agreementUnregistered share saleBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Acquisition or sale completedDirectors and officersMaterial agreementUnregistered share saleBylaws or fiscal year changed | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Delisting notice | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Jul 20, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | · | · | · | · | · | · | · | · | 29 | · | · | · | 29 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 29 people (70% of workforce) | Restructuring planSEC 8-K | “In connection therewith, on September 20, 2023, the Board of Directors (the “Board”) of the Company approved a restructuring plan (the “Restructuring Plan”), pursuant to which the …” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
Discuss Damora Therapeutics, Inc.#
1 automatic updates and 0 member comments. Sign in to comment and react.
- Mutual funds: 84 funds hold $321 millionautomatic update · Jul 31, 2026
84 mutual funds in 1 country hold shares of Damora Therapeutics, Inc. worth $321 million, about 5.7% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 68 funds added shares and 0 sold; on balance they bought $137 million. Share splits are not counted as trading.
How Damora Therapeutics, Inc. compares in Biotechnology
- Market cap$1.3 B · higher than 72% of 726
- Price / book5.5× · lower than 28% of 534
- FCF yield-3.3% · higher than 76% of 449
- 🇺🇸 Cullinan Oncology, Inc.$1.3 B
- 🇺🇸 LB Pharmaceuticals Inc$1.3 B
- 🇺🇸 Vor Biopharma Inc.$1.3 B
- 🇩🇪 Formycon AG$1.3 B
- 🇳🇱 Pharming Group N.V.$1.3 B
- 🇺🇸 Nektar Therapeutics$1.3 B
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Damora Therapeutics, Inc.🇩🇰 | $1.3 B | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Cullinan Oncology, Inc.$1.3 B
- LB Pharmaceuticals Inc$1.3 B
- Vor Biopharma Inc.$1.3 B
- Formycon AG$1.3 B
- Pharming Group N.V.$1.3 B
- Nektar Therapeutics$1.3 B
Sources and freshness
- Market cap:
- Oct 26, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Damora Therapeutics, Inc.? Verify and update this profile — free
Show Damora Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.